Despite the promising preclinical results that have demonstrated TanIIA activates the Nrf2 pathway and ameliorates different fibrotic processes in IPF models, there are no clinical trials on TanIIA. This evidence concerns the gene NFE2L2 and idiopathic pulmonary fibrosis.